Efficacy of Roflumilast on Exacerbations in Patients With Non-cystic Fibrosis Bronchiectasis
NCT ID: NCT04122547
Last Updated: 2019-10-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
40 participants
INTERVENTIONAL
2015-01-31
2015-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Roflumilast in Non-CF Bronchiectasis Study
NCT03428334
Effect of Roflumilast at Acute Exacerbations of Chronic Obstructive Pulmonary Disease
NCT01473758
Roflumilast in Non-CF Bronchiectasis Study (2019)
NCT04322929
Assessment of Early Outcomes of Roflumilast in Patients With Non Cystic Fibrosis Bronchiectasis
NCT04090294
Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease. Ratio-Study. (BY217/M2-112)
NCT00430729
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Roflumilast
Roflumilast 500 microgram one tab oral per day
Roflumilast
Active drug
Placebo
One tablet oral per day
Placebo
Placebo one tablet oral od
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Roflumilast
Active drug
Placebo
Placebo one tablet oral od
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* history at least 2 exacerbation last year
Exclusion Criteria
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Prince of Songkla University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Siwasak Juthong
Clinical Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kanung Saejiam, MS
Role: STUDY_DIRECTOR
Prince of Songkla University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Songklanagarind hospital
Songkhla, , Thailand
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
25132558
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.